SAN FRANCISCO, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that a blood test based on the Company’s humanized antibody, clivatuzumab, correctly identified nearly two thirds of patients with early stage pancreatic cancer. Dr. David V. Gold, Director of Laboratory Administration and Senior Member of the Garden State Cancer Center in Morris Plains, NJ, presented the study at the 2012 Gastrointestinal Cancers Symposium media presscast. The scientific presentation will be given on January 20, 2012.
